These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21190142)

  • 21. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
    Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
    [No Abstract]   [Full Text] [Related]  

  • 23. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
    Vitolo U; Chiappella A; Angelucci E; Rossi G; Liberati AM; Cabras MG; Botto B; Ciccone G; Gaidano G; Falchi L; Freilone R; Novero D; Orsucci L; Pavone V; Pogliani E; Rota-Scalabrini D; Salvi F; Tonso A; Tucci A; Levis A;
    Haematologica; 2009 Sep; 94(9):1250-8. PubMed ID: 19586937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
    Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
    Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of diffuse large B cell lymphoma.
    Kwak JY
    Korean J Intern Med; 2012 Dec; 27(4):369-77. PubMed ID: 23269875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
    Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
    Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
    Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
    Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era.
    Mounier N; Gisselbrecht C
    Curr Opin Oncol; 2011 Mar; 23(2):209-13. PubMed ID: 21169834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.
    Matsuo T; Tanaka T; Fujii N
    J Clin Exp Hematop; 2017; 56(3):170-175. PubMed ID: 28331132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
    Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.